Alerta

Johnson & Johnson (JNJ)

NYSE: JNJ · Precio en tiempo real · USD

260.60

-1.48 (-0.56%)

Al cierre: Aug 14, 2026, 10:00 AM

-0.56% (1D)

Precio de compra	260.39
Capitalización de mercado	628.01B
Ingresos (TTM)	97.93B
Beneficio neto (TTM)	21.04B
Beta	0.23
EPS (TTM)	8.62
Ratio PER (TTM)	30.23
Adelante PE	21.17
P/B (TTM)	7.39
P/S (TTM)	6.41
Earnings Date	Oct 13, 2026

Precio de venta	260.78
Volumen	392,463
Volumen medio (20D)	8,205,127
Abierto	260.65
Anterior Cerrar	262.08
Rango del día	259.90 - 261.63
Rango de 52 semanas	173.33 - 274.90
analista	Buy
Precio objetivo	280 (7.44%)
Dividendos	$5.36 (2.05%)
Fecha ex dividendo	25 ago 2026

Acerca de JNJ

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed th...

[Leer más]

Industria Drug Manufacturers - General

Sector Healthcare

IPO Fecha n/a

Empleados 138,200

Bolsa de Valores NYSE

Símbolo bursátil JNJ

Sitio web https://www.jnj.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Johnson & Johnson fueron 94.19B, un aumento de 6.05% en comparación con 88.82B del año anterior. Las ganancias fueron 26.8B, un aumento de 90.56%.

Estados financieros

Pronóstico del analista

Según las calificaciones de los analistas de 22, la calificación promedio de las acciones de JNJ es "Buy". El pronóstico del precio de las acciones a 12 meses es 280, que es Potencial alcista de 7.44% del último precio.

Previsiones bursátiles

Sorpresa de resultados

Johnson & Johnson ha publicado sus resultados trimestrales en Jul 15, 2026:

Ingresos de $25.31B falla las estimaciones por $0, con 6.60% Crecimiento interanual.

EPS de 2.9 supera las estimaciones en 0.05, con 4.69% Crecimiento interanual.

Próxima publicación de resultados

Está previsto que Johnson & Johnson publique sus resultados el Oct 13, 2026, antes de que se abra el mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

Justo ahora · 24/7 Wall St.

5 Dividend Kings to Buy and Hold Forever in August

Fifty-plus years of unbroken dividend raises sounds like a floor, but not every Dividend King deserves a permanent seat in your portfolio right now. Five do, and one of them is actually trading at a d...

Justo ahora · 24/7 Wall St.

How a Retired Couple Collects $11,500 a Month and Never Pays an IRMAA Surcharge

Medicare's IRMAA surcharge punishes a single dollar of overage with a full bracket jump and no phase-in, yet some retirees collect six figures annually and never trigger it. The strategy depends on ho...

10 horas hace · Insider Monkey

Johnson & Johnson (JNJ)’s $5.5B Talc Settlement: Turning Point or Temporary Relief?

The World Health Organization projects that the share of the world’s population aged 60 years and older will almost double from 12% in 2015 to 22% by 2050. The Population Reference Bureau expects the ...

12 horas hace · Trefis

How Much More Can Boston Scientific Stock Move After Losing Half Its Value?

Options price a band whose floor sits below anything the stock has touched in the past year, and the company's own recovery timetable lands after that window closes.

12 horas hace · 24/7 Wall St.

How a 64-Year-Old Turned an $880,000 401(k) Rollover Into a $5,200 Monthly Paycheck Without Buying an Annuity

Rolling $880,000 into a self-directed IRA sounds like a clean break from the 9-to-5, but generating $5,200 a month from that balance forces a choice between safety and survival that most retirement ca...

Página 1 de 2

Johnson & Johnson (JNJ)